Danaher’s Cepheid gets first WHO prequalification nod for TB tests
Cepheid Inc., a US molecular diagnostics company and a wholly-owned arm of Danaher Corporation has been granted WHO prequalification for its diagnostic tests.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Cepheid Inc., a US molecular diagnostics company and a wholly-owned arm of Danaher Corporation has been granted WHO prequalification for its diagnostic tests.
Tuberculosis has emerged as the world’s top infectious disease with about 8.2 million people newly diagnosed with the illness last year — the.
HQ Team September 27, 2024: World leaders convened at the United Nations General Assembly (UNGA) on September 26, to address the escalating threat.
A family of antimicrobial compounds can neutralise necrotising fasciitis, a deadly bacterial skin infection that is also known as flesh-eating disease, when tested.
HQ Team August 4, 2024: The WHO has warned about the rising global incidence of hypervirulent and multi-resistant Klebsiella Pneumoniae (hvKp) infections. The.
HQ Team May 7, 2024: A target of one billion additional people enjoying better health and well-being is likely to be met by.
HQ Team July 26, 2023: Better access to testing and diagnostic services is required to prevent sexually transmitted infections (STI) being acquired by.
HQ Team June 1, 2023: Pfizer’s last-stage experimental trials for treating multi-drug-resistant bacteria have yielded positive results, the US-based company announced. The Phase.
Antimalarial drug resistance in Africa is a severe cause for concern and parasite resistance to artemisinin medicine has emerged in the Greater Mekong.
Tuberculosis, the second deadliest infectious killer after Covid-19, claimed 1.6 million lives last year, including 187,000 HIV-positive patients, according to the WHO's 2022.